Marcelo Pasquini

Director: Blood and Marrow Transplantation & Cellular Therapies Program, Hematology/Oncology, Cleveland Clinic Taussig Cancer Institute · Case Western Reserve University

Credentials: · · · · ·

History

Hematology/Oncology · Case Western Reserve University
Present

Internal Medicine
Jackson Memorial Hospital
1997–2000
FUND UNIV ESTADUAL DE LONDRINA, CENT DE CIEN, LONDRINA, PR, BRAZIL
1993–1997
Hematology
Univ of Utah Sch of Med
1993–1996

Research

ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
Review · Biology of Blood and Marrow Transplantation · 2019 · 3,048 citations
Defining the intensity of conditioning regimens: working definitions
Biology of Blood and Marrow Transplantation · 2009 · 1,558 citations
Lenalidomide after stem-cell transplantation for multiple myeloma
New England Journal of Medicine · 2012 · 909 citations

Parameswaran Hari
70 papers
Mary Horowitz
59 papers
Anita D'Souza
51 papers · 1 as a fellow
Philip McCarthy
46 papers
Wael Saber
46 papers
Binod Dhakal
36 papers
Daniel Weisdorf
36 papers
Saurabh Chhabra
36 papers
SG
Sergio Giralt
34 papers
Edward Stadtmauer
32 papers
Hillard Lazarus
30 papers
James Rizzo
27 papers

Grants

A Data Resource for Blood and Marrow Transplants and Adoptive Cellular Therapy Research
National Cancer Institute · U24
PI · $14.7M · Medical College of Wisconsin
1998–2028
Immuno-Oncology Translation Network (IOTN): Cellular Immunotherapy Data Resource (CIDR)
National Cancer Institute · U24
Contact PI · $9M · Medical College of Wisconsin
2018–2023
Ancillary Studies in Clinical Trials - PRIMeR
National Heart, Lung, and Blood Institute · R01
Contact PI · $1.5M · Medical College of Wisconsin
2011–2016

Clinical trials

A Study of Tacrolimus/Methotrexate and Tocilizumab to Prevent Acute Graft-Versus-Host Disease (AGVD) After Allogeneic Hematopoietic Stem Cell Transplant
Principal investigator · Completed · Phase 2
William R. Drobyski, MD
2014–2018
Safety Study of Lenalidomide Maintenance Therapy Post Allogeneic HCT for High-risk Multiple Myeloma
Study chair · Completed · Phase 2
Center for International Blood and Marrow Transplant Research
2009–2014
Upfront Chimeric Antigen Receptor T-Cell to Upgrade Response in Multiple Myeloma
Study director · Completed · Phase 2
Medical College of Wisconsin
2022–2025